Advertisements

Nebivolol Generis

Quick links to important sections

Nebivolol Generis

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Nebivolol Generis

Property Description
Active ingredient Nebivolol hydrochloride
Form Oral tablet
Pharmacological class Third-generation Beta-blocker (beta-adrenergic receptor antagonist)
General purpose Cardiovascular stability and optimization
Origin Synthetic organic compound

Nebivolol Generis: Classification and Pharmaceutical Identity

Nebivolol Generis is a prescription-only pharmaceutical preparation containing the active chemical substance, Nebivolol hydrochloride, supplied primarily as an oral tablet. This medicine belongs to the broad pharmacological class of beta-adrenergic receptor antagonists, commonly known as beta-blockers, a group of agents used to modulate cardiovascular function. Its single-agent status focuses the therapy solely on the effects of Nebivolol. The product is derived from a synthetic organic compound and is classified as a generic preparation, confirming its adherence to the International Nonproprietary Name (INN) standard.

What Makes Nebivolol a Third-Generation Beta-Blocker?

The structural features of Nebivolol distinguish it as a third-generation beta-blocker, characterized by its distinctive dual action. This profile includes highly selective beta1 receptor affinity in the heart, combined with a secondary mechanism that affects the blood vessels. This differentiation arises because Nebivolol promotes vasodilation through increasing the bioavailability of nitric oxide (NO). This mechanism offers additional vascular benefits compared to basic beta1-selective agents.

General Purpose of Nebivolol Generis as a Cardiovascular Agent

The general therapeutic purpose of Nebivolol Generis is to support cardiovascular stability by balancing the forces that regulate blood flow and heart activity. Its fundamental function is achieved through controlled beta1-blockade, which reduces the workload on the heart muscle. Simultaneously, the compound's vasodilatory property helps to ease peripheral vascular tension. This combined effect is clinically recognized for its role in optimizing circulatory system function in typical scenarios requiring long-term heart support.

Regulatory References

  1. \beta-adrenergic receptor antagonists
  2. highly selective \beta1 receptor affinity
  3. National Library of Medicine - MedlinePlus
Advertisements

What side effects are possible with Nebivolol Generis?

Possible Side Effects and Safety Information

Nebivolol Generis's safety profile is documented through regulatory classification of adverse reactions, categorized by their frequency and the system they affect. The frequencies are derived from clinical trials, typically classified using standard regulatory definitions.

Frequency-Classified Adverse Reactions

The most Common side effects reported in official labeling (occurring in 1% to 10%) include headache, dizziness, paresthesia (tingling or numbness), fatigue, edema, dyspnea (difficulty breathing), and gastrointestinal complaints such as constipation, diarrhea, and nausea. A Very Common reaction (occurring in ge 10%) when treating chronic heart failure is bradycardia (slow heart rate).

Uncommon reactions (0.1% to 1%) involve the aggravation of heart failure, orthostatic hypotension (dizziness upon standing), bronchospasm, depression, and impotence.

Serious Safety Constraints and Population Notes

The official labeling documents the risk of serious cardiac events (e.g., exacerbation of angina pectoris, myocardial infarction) following the abrupt cessation of therapy, especially in patients with existing coronary artery disease. The use of Nebivolol Generis is formally restricted or contraindicated in individuals with severe hepatic impairment, decompensated cardiac failure, second- or third-degree heart block, and severe asthma or chronic obstructive pulmonary disease (COPD).

Additionally, the beta-blocking activity may mask the symptoms of hypoglycemia in patients with diabetes mellitus, and the signs of hyperthyroidism, such as tachycardia. Safety and efficacy are not established for the pediatric population.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define Nebivolol overdose by severe, life-threatening manifestations resulting from excessive beta-blockade. Individuals exposed above the prescribed dose must seek immediate medical consultation for treatment.

Documented Manifestations and Severe Outcomes:

Overdose may present as a critical cardiovascular event, including profound severe bradycardia (excessively slow heart rate) and hypotension (extremely low blood pressure). Official labeling also cites the risk of cardiac conduction disturbances, such as Second- or Third-degree Atrioventricular (AV) Block, and the progression to worsening heart failure, acute pulmonary oedema, or cardiogenic shock. Respiratory compromise, such as bronchospasm, is also a documented risk.

Emergency Actions and Supportive Management:

Regulatory mandates require that emergency services or poison control be contacted for guidance on beta-blocker overdose treatment. Management is defined as symptomatic and supportive treatment to stabilize the patient. Interventions for severe manifestations may include placing the patient in a supine position and administering intravenous normal saline to counter severe hypotension, or, in extreme cases of treatment-resistant bradycardia, the consideration of pacemaker insertion is a documented procedure. The regulatory documentation does not list a specific antidote; therefore, care focuses entirely on continuous physiological stabilization.

Advertisements

Therapeutic Uses of Nebivolol Generis

What Nebivolol Generis Treats: Main Uses and Benefits

Nebivolol Generis is commonly used to help with conditions characterized by periods of heightened physiological stress, providing supportive relief that helps ease the overall symptom burden. The medication is applied across domains where additional symptomatic support is needed, including key therapeutic areas like essential hypertension and cardiac symptom domains.

The medication is commonly used to help with the symptomatic management of essential hypertension. This approach is relevant when symptoms related to systemic imbalance create noticeable physiological strain, assisting with maintaining functional stability.

“It is applied in addressing symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”

It is considered relevant in conditions involving recurrent or episodic manifestations, where it helps ease symptoms that interfere with daily comfort. This supportive role helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Heightened Symptoms Nebivolol Generis is often used when symptoms intensify and supportive relief is needed, providing assistance with maintaining functional stability.


Advertisements

Eligibility and Restrictions for Use

Official Eligibility Status for Nebivolol Generis

Nebivolol Generis is formally approved for use in adult patients with hypertension. Its eligibility is constrained by age, pre-existing health conditions, and organ function, as defined in official regulatory documents. Use in children and adolescents (under 18 years) is not recommended because safety and effectiveness have not been established by health authorities.


Absolute Contraindications

The medicine is contraindicated (must not be used) in patients with several severe pre-existing heart conditions. These include severe bradycardia (very slow heart rate), heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, or sick sinus syndrome unless a permanent pacemaker is in place. Additionally, the drug is prohibited for individuals with severe hepatic impairment (severe liver disease) and those with a known hypersensitivity to the product.


Conditional Use and Restrictions

The label mandates caution for patients with specific comorbidities. Individuals with diabetes or hyperthyroidism should be monitored closely, as Nebivolol Generis may mask clinical signs, such as tachycardia. For patients with moderate hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min), a lower initial dose is required. The drug is generally not recommended during lactation, as it passes into breast milk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nebivolol Generis's interaction profile is characterized by pharmacokinetic effects, primarily involving metabolism, and pharmacodynamic synergy with other cardiovascular agents, as documented in official prescribing information.

Officially Contraindicated Combinations

  • Verapamil and Diltiazem-type Calcium Channel Blockers: Co-administration is formally prohibited in regulatory documents due to the significant risk of excessive reduction in heart rate, blood pressure, and cardiac contractility. This represents a severe pharmacodynamic interaction.
  • Severe Hepatic Impairment: Use is contraindicated in patients with severe hepatic impairment (Child-Pugh Class >B) because the resulting decrease in drug metabolism leads to substantial drug accumulation and risk of adverse effects.

Interactions Altering Drug Exposure

  • CYP2D6 Inhibitors: Co-administration with strong inhibitors of the CYP2D6 enzyme, such as Fluoxetine and Paroxetine, significantly increases Nebivolol plasma levels and exposure (AUC). Other inhibitors like Quinidine and Propafenone are noted for this pharmacokinetic mechanism. Conversely, Cimetidine increases d-nebivolol plasma levels by approximately 23%.

Pharmacodynamic Interaction Risks

  • Digitalis Glycosides and Catecholamine-Depleting Drugs (e.g., Reserpine): These combinations carry an additive risk of excessive slowing of the heart rate (bradycardia) or excessive reduction of sympathetic activity.
  • Anesthetic Agents: Certain general anesthetic agents that depress myocardial function may augment the risks associated with beta-blockade during major surgery.

Timing and Procedural Restrictions

  • Clonidine: Regulatory documents mandate that Nebivolol must be formally withdrawn for several days before the gradual tapering of Clonidine can commence.
  • Antacids (e.g., Aluminum Hydroxide): To prevent inhibition of gastrointestinal absorption, Nebivolol should be administered separately from antacids by a minimum of 2 hours.
Advertisements

Mechanism of Action

How Nebivolol Generis Works

Nebivolol Generis acts through a dual mechanism that modulates key cardiovascular regulatory systems at the molecular level, defining its third-generation classification. The action involves two complementary physiological changes.

Selective Modulation of Cardiac Sympathetic Activity

This domain covers the drug's action as a highly selective blocker (antagonist) of the beta1-adrenergic receptor, primarily located on the heart and in the kidney. By engaging in antagonism at this site, the drug dampens the excitatory signaling from the sympathetic nervous system and suppresses the release of renin. The physiological consequence of this molecular cascade is a reduction in heart rate and decreased force of contraction, which results in a reduction of cardiac workload and oxygen demand.

Endothelial-Mediated Vascular Potentiation

A unique secondary mechanism involves the drug's ability to stimulate the synthesis of Nitric Oxide (NO) within the vascular lining (endothelium), largely via interaction with the beta3-adrenergic receptor and the enzyme eNOS. This activation augments the L-Arginine/Nitric Oxide pathway, resulting in the relaxation of vascular smooth muscle. This effect leads to systemic vasodilation and a subsequent reduction in the resistance against which the heart pumps. The two mechanisms—cardiac slowing and vasodilation—are complementary actions that influence circulatory dynamics.

Advertisements

Dosage and Administration Information

How to Use Nebivolol Generis

Nebivolol Generis is designated for oral administration in the form of a tablet. The medicine is taken once daily and must be administered at the same time each day to maintain a consistent therapeutic pattern. The tablet may be swallowed with a glass of water and can be taken with or without food.


Official Dosing and Use Patterns

The usage pattern involves a slow, gradual adjustment of the dose over time. The onset of the full blood pressure-lowering effect may require up to four weeks of consistent administration.

Indication Initial Daily Dose Titration Intervals Maximum Daily Dose
Essential Hypertension 5 mg May increase at 2-week intervals 40 mg
Chronic Heart Failure 1.25 mg Double dose at 1- to 2-weekly intervals 10 mg

Special Procedural Requirements

Specific modifications are established for patient subsets. For individuals with severe renal impairment or moderate hepatic impairment, the initial recommended dose is 2.5 mg once daily, followed by slow upward titration. Similarly, for older adults (over 65 years), a lower starting dose (2.5 mg) is often used for hypertension management.

If discontinuation of therapy is necessary, standard protocols involve a gradual reduction in dose (tapering) over a period of 1 to 2 weeks. Abrupt cessation is not part of the standardized protocol. Furthermore, the initiation and subsequent dose increases for chronic heart failure treatment are performed under close medical supervision. If a dose is missed, the recommended procedure is to skip the missed dose and resume the normal schedule at the next designated time.

Advertisements

Recent Clinical Evidence

The clinical research for Nebivolol Generis has primarily explored its role in two areas: Essential Hypertension and Stable Chronic Heart Failure (CHF).


Evidence for Use in Essential Hypertension

Research explored Nebivolol Generis in the context of essential hypertension, and primarily consists of randomized, controlled trials. These studies examined short-term changes in key physiological measurements in populations of adults with mild to moderate high blood pressure. Outcomes monitored outcomes related to systemic or functional imbalance over defined time intervals, typically lasting between 8 and 12 weeks. Findings describe patterns observed in the studies related to measured blood pressure and heart rate values.

A key research limitation is that follow-up durations were limited in these initial trials. Consequently, limited long-term data are available regarding the assessment of complex cardiovascular outcomes, such as stroke or heart attack. Subgroup findings were uncertain, including some heterogeneity noted in measured response across different racial subgroups.


Evidence for Use in Stable Chronic Heart Failure

A central part of the evidence comes from a large-scale, long-term, randomized, placebo-controlled trial that primarily focused on an older adult population (70 years and above). The studies were designed to assess a combined endpoint related to all-cause mortality or cardiovascular hospital admission, as well as functional measures like the heart’s pumping capacity (LVEF).

Analyses described patterns observed in all-cause death as a stand-alone outcome; however, findings indicated that the difference in this measurement alone was not determined to be statistically significant in the main trial. Research highlights changes measured in LVEF and shifts in patient-reported functional status during the study period. Data for younger groups of patients with chronic heart failure remain insufficient.


Research Limitations and Uncertainty

The overall evidence landscape highlights several research limitations. Long-term changes and functional outcomes are not fully established, particularly for hypertension, where follow-up durations were limited to a few months. Evidence quality varies across studies, and certainty remains low regarding outcomes beyond those measured in the controlled trial settings. Research provides context but not individual predictions.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Chronic heart failure in adults: diagnosis and management
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nebivolol Generis (FAQ)


Q: How quickly does Nebivolol Generis start to lower blood pressure?

Official information indicates that while an initial effect on blood pressure may be observed shortly after starting treatment, the full therapeutic benefit may take up to four weeks of consistent use. The importance of consistent, daily administration is highlighted in the product's official prescribing information.


Q: Can Nebivolol Generis cause weight gain or weight loss?

Rapid weight gain is a serious, though uncommon, side effect noted in post-marketing reports. Any concerns about this should be discussed with a healthcare professional. More generally, unusual weight changes, whether gain or loss, may occur during treatment.


Q: How long do I need to take Nebivolol Generis before seeing the full effect?

According to regulatory guidelines, the full effect of the medicine on your blood pressure may take up to four weeks to fully materialize. Nebivolol Generis is intended for long-term management of chronic conditions. Consistent, daily use is key to achieving and sustaining the intended therapeutic effect.


Q: Are there any specific foods or supplements I should avoid with Nebivolol Generis?

Regulatory information advises that certain supplements, such as those containing minerals (often found in multivitamins), may need to be separated from your Nebivolol dose by at least two hours. Similarly, antacids should be separated by at least two hours, and official recommendations suggest they be taken at least two hours apart to help ensure proper absorption of Nebivolol Generis.


Q: Will Nebivolol Generis make me feel tired or dizzy during the day?

Official safety information lists tiredness (fatigue) and dizziness as common side effects reported by patients in clinical trials. These effects are often reported when treatment begins or when the dose is changed.


Q: Can Nebivolol Generis be taken at night, and is it better than morning dosing?

Official administration instructions specify that the medicine should be taken once daily and at the same time each day to help maintain consistent levels in the body. The regulatory documents do not specify whether morning or night dosing is clinically superior.


Q: Does Nebivolol Generis cause any sexual side effects in men or women?

Official safety data lists impotence (erectile dysfunction) as an uncommon side effect for patients taking the medication.


Q: Is it safe to take ibuprofen or other NSAIDs with Nebivolol Generis?

Regulatory labeling cautions that the use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may potentially reduce the blood pressure-lowering effect of Nebivolol Generis.


Q: Is Nebivolol Generis known to cause vivid dreams or sleep disturbances?

Official safety information notes that insomnia (difficulty sleeping) and nightmares have been reported as uncommon side effects while taking Nebivolol Generis.


Q: Does Nebivolol Generis interact with alcohol, even in small amounts?

Yes. According to official warnings, alcohol can increase the blood pressure-lowering effects of the drug. The combination carries a risk of potentially excessive blood pressure drops and associated symptoms like dizziness, headache, or fainting.


Q: How long does Nebivolol Generis stay in your system after taking it?

Regulatory pharmacokinetic data shows that the half-life of Nebivolol varies based on how quickly a person metabolizes the drug. For most people, the half-life is approximately 12 hours, while it can be about 19 hours for those who metabolize it more slowly.


Q: Can I take cold and flu medicine while on Nebivolol Generis?

Many over-the-counter cold and flu preparations contain sympathomimetic agents, which can potentially increase blood pressure. Official warnings note that combining these types of agents with Nebivolol Generis may potentially counteract its intended blood pressure-lowering effect.


Q: Will taking Nebivolol Generis affect my ability to drive or operate machinery?

Because Nebivolol Generis can cause common side effects such as dizziness and tiredness, the official label suggests exercising caution. Patients should understand how the medication affects them before driving or performing other tasks that require full alertness.


Q: Can Nebivolol Generis interact with herbal supplements like St. John's Wort?

Nebivolol is metabolized in the liver by the CYP2D6 enzyme. Regulatory documents warn that taking the medicine alongside strong inhibitors of this enzyme, which can include certain herbal supplements, may potentially lead to increased levels of Nebivolol in the bloodstream.


Q: What proof or studies show that Nebivolol Generis is effective for heart failure?

Nebivolol's indication for Chronic Heart Failure is supported by a large-scale, long-term, randomized, placebo-controlled clinical trial. This trial primarily focused on older adult populations and assessed outcomes related to death and cardiovascular hospitalization.


Q: Are generic Nebivolol Generis tablets the same strength and quality as the brand name?

Yes. Generic drug regulations require that generic preparations, like Nebivolol Generis, must demonstrate bioequivalence to the original brand-name medication. This means they must contain the same active ingredient, be the same strength, and meet the same strict standards for quality and performance.


Q: How often do people need to have their liver enzymes checked while on Nebivolol Generis?

Official prescribing information notes that the drug is prohibited for use in severe liver disease (hepatic impairment). Post-marketing reports include abnormal liver function. Specific monitoring frequency is determined by the healthcare provider.


Q: Does Nebivolol Generis cause fluid retention or swelling?

Official safety data lists edema, which is swelling caused by fluid retention, as a common side effect reported in patients taking Nebivolol Generis.


Q: Can people with kidney problems take Nebivolol Generis?

Yes, but caution is advised. Official labeling states that a lower initial dose is required for individuals who have severe renal impairment (significant kidney function reduction). The physician determines the appropriate starting dose.


Q: Why do some people need a combination of Nebivolol Generis and another drug?

Nebivolol Generis is indicated for the treatment of high blood pressure, and often in clinical practice, combining two or more medications may be necessary to achieve desired therapeutic goals. The drug is commonly used alongside other cardiovascular medicines, such as diuretics.


Q: Can Nebivolol Generis be prescribed for teenagers or children?

No. Official regulatory information states that the safety and effectiveness of Nebivolol Generis have not been established in the pediatric population. The drug is not recommended for use in children and adolescents under 18 years of age.


Q: Why is my doctor asking me to monitor my heart rate while on this medication?

Nebivolol Generis is a beta-blocker that primarily works by reducing heart rate. Bradycardia (slow heart rate) is a common, and in heart failure treatment, a very common, side effect. This monitoring helps the healthcare provider assess the drug's effect and ensures the heart rate is within an appropriate range.


Q: Can Nebivolol Generis cause depression or changes in mood?

Yes, official safety information lists depression as an uncommon side effect. Other reported central nervous system effects, such as nervousness and insomnia, may also be experienced.


Q: Does Nebivolol Generis treat the cause of high blood pressure or just the symptoms?

Nebivolol Generis is indicated for the treatment of essential hypertension. It works by modulating key systems that regulate blood flow and heart activity, controlling blood pressure and heart function, which is the standard approach for managing chronic high blood pressure.


Q: Can I take antacids or heartburn medicine with Nebivolol Generis?

Antacids, such as aluminum hydroxide, can interfere with the body's absorption of Nebivolol Generis. To ensure the medication works correctly, official guidelines recommend that antacids be taken at least two hours apart from the Nebivolol dose.


Q: Does Nebivolol Generis affect cholesterol levels?

As Nebivolol Generis belongs to the beta-blocker class of medicines, regulatory documents note that such agents may alter serum lipid profiles. This can involve changes such as increases in triglycerides and LDL cholesterol or decreases in HDL cholesterol.


Q: Is it normal to feel a tingling sensation in my hands or feet on Nebivolol Generis?

Yes. Paresthesia, which describes a tingling or numbness sensation, is listed in the official safety profile as a common side effect reported in clinical trials.

Advertisements

How should Nebivolol Generis be stored and disposed of?

Nebivolol tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling permits brief temperature excursions between 15 C and 30 C.

Storage Requirements

  • Temperature Control: Store the medicine in a closed container at room temperature, away from excess heat and moisture.
  • Environmental Protection: Keep the tablets in a dry place and ensure they are protected from freezing.
  • Packaging Rules: The container must be kept tightly closed to maintain product integrity and stability.
  • Child Protection: The product must be stored out of the sight and reach of children, as required by official labeling.

Disposal Instructions

  • Proper Discarding: Expired or unused tablets should not be disposed of in household trash or flushed down the toilet, unless specifically advised by a healthcare professional.
  • Authorized Collection: Discarding must align with local guidelines for pharmaceutical waste or utilize authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nebivolol Generis found in:

A-Z Index: